Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X ...

September 9, 2024

Natera to present new Signatera MRD test data at 2024 ESMO Congress, including updated CIRCULATE-Japan GALAXY trial results showing significant OS advantage for Signatera-negative CRC patients.

Highlighted Terms

colorectal liver metastases Squamous Cell Carcinoma of the Head and Neck locally advanced MMR-deficient (dMMR) colon cancer neoadjuvant therapy colorectal cancer Natera resectable colorectal cancer Colorectal Cancer Breast Cancer neoadjuvant immunotherapy adjuvant chemotherapy Elacestrant ER+/HER2- breast cancer locally advanced SCCHN ESMO

Related News

quantisnow.com

Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X ...

Natera to present new Signatera MRD test data at 2024 ESMO Congress, including updated CIRCULATE-Japan GALAXY trial results showing significant OS advantage for Signatera-negative CRC patients.